The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 335:775-782 September 12, 1996 Number 11
NextNext

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients with unstable angina or acute myocardial infarction.

Methods At 373 hospitals in 13 countries, 12,142 patients with acute coronary syndromes were randomly assigned to 72 hours of therapy with either intravenous heparin or hirudin. Patients were stratified according to the presence of ST-segment elevation on the base-line electrocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic considered to indicate unstable angina or non–Q-wave myocardial infarction.

Results At 24 hours, the risk of death or myocardial infarction was significantly lower in the group assigned to hirudin therapy than in the group assigned to heparin (1.3 percent vs. 2.1 percent, P = 0.001). The primary end point of death or nonfatal myocardial infarction or reinfarction at 30 days was reached in 9.8 percent of the heparin group as compared with 8.9 percent of the hirudin group (odds ratio for the risk of the end point in the hirudin group, 0.89; 95 percent confidence interval, 0.79 to 1.00; P = 0.06). The predominant effect of hirudin was on myocardial infarction or reinfarction and was not influenced by ST-segment status. There were no significant differences in the incidence of serious or life-threatening bleeding complications, but hirudin therapy was associated with a higher incidence of moderate bleeding (8.8 percent vs. 7.7 percent, P = 0.03).

Conclusions For acute coronary syndromes, recombinant hirudin provided a small advantage, as compared with heparin, principally related to a reduction in the risk of nonfatal myocardial infarction. The relative therapeutic effect was more pronounced early (at 24 hours) but dissipated over time. The small benefit was consistent across the spectrum of acute coronary syndromes and was not associated with a greater risk of major bleeding complications.


Source Information

Dr. Topol, as study chairman, is responsible for the content of the article.

Address reprint requests to Dr. Eric J. Topol at the Cleveland Clinic Foundation, Dept. of Cardiology F/25, 9500 Euclid Ave., Cleveland, OH 44195.

Full Text of this Article


Related Letters:

Heparin versus Hirudin for Acute Coronary Syndromes
Schmaier A. H., Topol E. J., Califf R. M., Van de Werf F., The GUSTO IIb Investigators
Extract | Full Text  
N Engl J Med 1997; 336:730-731, Mar 6, 1997. Correspondence

Coronary Artery Disease in Men and Women
Rosén M., Spetz C.-L., Hammar N., Greenland P., Goldbourt U., Cao L., Song W., Ornstein D. L., Zacharski L. R., Vaccarino V., Hochman J. S., Thompson T. D.
Extract | Full Text  
N Engl J Med 1999; 341:1931-1935, Dec 16, 1999. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.